லூட்ஸ் ெகேமன்ன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Novartis exhorté à coopérer sur la recherche et la production de médicaments
vietnam.vnanet.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietnam.vnanet.vn Daily Mail and Mail on Sunday newspapers.
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
sciencebusiness.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencebusiness.net Daily Mail and Mail on Sunday newspapers.
Novartis announces digital collaboration with Hewlett Packard Enterprise
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
The EMPHATHY clinical trial will enroll patients with COVID-19 to test the drug’s effectiveness in preventing worsening of symptoms and hospitalization.
Novartis and Molecular Partners have announced the start of their EMPATHY Phase II/III study to explore the use of its DARPin (designed ankyrin repeat proteins) therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis reportedly will run the trial program, with Molecular Partners serving as sponsor.
The EMPATHY clinical trial program is intended to investigate the safety and efficacy of ensovibep in COVID-19 in the early stages of infection, with the goal of worsening symptoms and hospitalization. According to the companies, the study will enroll 400 patients in Phase II to determine a dose with optimal safety and activity; initial results are expected in August 2021.